CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
侵袭性 NK 细胞白血病治疗和预后进展：ANKL22 研究结果
英文原题：Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
查看英文原题
Advances in the treatment and prognosis of aggressive NK-cell leukemia: results from the ANKL22 study.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
侵袭性NK细胞白血病（ANKL）是一种罕见NK细胞白血病，具有侵袭性临床病程，且常与EB病毒相关。研究者回顾性收集了2000—2021年71家机构诊断的126例ANKL患者，其中108例可供分析，以描述近期治疗进展。患者年龄中位数49岁（范围17–90岁），男性63例。骨髓及外周血白血病细胞比例中位数分别为19.7%和10.0%。一线方案包括SMILE（38例，42%）、CHOP类（26例，29%）、DeVIC（15例，17%）及其他含L-门冬酰胺酶方案（8例，9%），总体缓解率分别为66%、31%、33%和50%。总生存期（OS）中位数为5.5个月，2年OS率为18.7%。接受SMILE治疗的患者OS显著优于其他方案（2年OS率30.1%比7.0%；P<0.001）。异体造血干细胞移植（HSCT）后预后进一步改善（2年OS率37.2%比3.5%；P<0.001）。多变量分析确认SMILE治疗[风险比（HR）0.53，95%置信区间（CI）0.31–0.88]和异体HSCT（HR 0.33，95% CI 0.18–0.61）为独立有利因素。
总之，SMILE化疗后序贯异体HSCT可能改善ANKL患者结局。
展开英文摘要原文
Aggressive NK-cell leukemia (ANKL) is a rare NK-cell leukemia characterized by, an aggressive clinical course, and frequent Epstein-Barr virus association.
We retrospectively collected 126 ANKL patients diagnosed between 2000 and 2021 from 71 institutes; 108 were evaluable for analysis to characterize the recent advances. The median age was 49 years (range: 17-90), and 63 patients were male. The median percentage of leukemic cells in the bone marrow and peripheral blood was 19. 7% and 10. 0%, respectively. The first-line regimens included SMILE (n = 38, 42%), CHOP(-like) (n = 26, 29%), DeVIC (n = 15, 17%), and other L-asparaginase-containing regimens (n = 8, 9%), with the overall response rates of 66%, 31%, 33%, and 50%, respectively.
Median overall survival (OS) was 5. 5 months, with a 2-year OS of 18. 7%. Patients treated with SMILE had significantly better OS than others (2-year OS 30. 1% vs. 7. 0%; P < 0. 001). Prognosis further improved with allogeneic hematopoietic stem cell transplantation (HSCT) (2-year OS 37. 2% vs 3. 5%; P < 0. 001). Multivariate analysis confirmed treatment with SMILE [hazard ratio (HR) 0. 53, 95% confidential interval (CI) 0. 31-0. 88] and allogeneic HSCT (HR 0. 33, 95% CI 0. 18-0. 61) as independent favorable factors.
In conclusion, SMILE chemotherapy followed by allogeneic HSCT may improve outcomes in ANKL.
论文信息
- 作者
- Fujimoto A、Maeda T、Doki N、Fukuhara N、Iwaki N、Hiramoto N、Goto H、Miyazaki T
- 单位
- Division of Hematology and Oncology, Department of Internal Medicine, Faculty of Medicine, Shimane University, Izumo, Japan. afujimot@med.shimane-u.ac.jp.Japan
- 期刊
- Leukemia2026 Feb
- 原文标识
- PubMed 41501503 · DOI 10.1038/s41375-025-02854-6